# Mesoblast Limited (MESO)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001345099 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001345099))
- Full page: https://inspectstocks.com/stocks/meso
- Data as of: price 2026-09-25; newest filing used 2026-02-27; latest fiscal period ended 2025-12-31

## Grade

**C-** on the growth-and-cash rubric, 3 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Revenue growing overall | passed | $65.4M | $7.5M |
| Revenue growing recently | passed | $65.4M | $17.2M |
| Free cash flow positive | failed | -$50.6M |  |
| Free cash flow growing overall | passed | -$50.6M | -$66M |
| Free cash flow growing recently | failed | -$50.6M | -$48.7M |

Business quality (the + / − mark): 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -156.2% |  |
| Healthy profit margin | failed | -156.2% |  |
| Good return on equity | failed | -17.1% |  |
| Debt under control | passed | 0.31 |  |
| Turns sales into cash | failed | -77.4% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $65.4M |
| Net income, trailing twelve months | -$102.1M |
| Free cash flow, trailing twelve months | -$50.6M |
| Net margin | -156.2% |
| Return on equity | -17.1% |
| Debt to equity | 0.31 |
| Diluted EPS, trailing twelve months | -$0.07 |
| Share price | $15.12 |
| Market value | $2B |
| Price / sales | 30.0x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/meso)
- [Financial statements](https://inspectstocks.com/stocks/meso/financials)
- [Competitors](https://inspectstocks.com/stocks/meso/peers)
- [Earnings](https://inspectstocks.com/stocks/meso/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.